Pravachol OTC Deal Reached Between Bayer, Bristol
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol will handle the regulatory filing of the switch NDA and advisory committee presentation for pravastatin 20 mg, while Bayer Consumer Care will handle OTC sales and marketing if FDA approves the cholesterol-lowering agent for nonprescription sale.
You may also be interested in...
Bristol Puts U.S. Consumer Business On The Selling Block
The company plans to contact potential buyers for the OTC business "over the coming weeks." Novartis and GSK are understood to be interested in Bristol's North American consumer business.
Bristol Puts U.S. Consumer Business On The Selling Block
The company plans to contact potential buyers for the OTC business "over the coming weeks." Novartis and GSK are understood to be interested in Bristol's North American consumer business.
Drug Safety Issues Will Raise Regulatory Expectations, Bristol Says
Bristol expects a more critical regulatory environment for its recently submitted muraglitazar NDA. Greater scrutiny by FDA could translate into more focused labeling, CEO Dolan says.